These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 24295872)

  • 1. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
    Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
    Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
    Yan H; Li W
    Dig Dis; 2015; 33(3):388-96. PubMed ID: 26045274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.
    Shimura S; Watashi K; Fukano K; Peel M; Sluder A; Kawai F; Iwamoto M; Tsukuda S; Takeuchi JS; Miyake T; Sugiyama M; Ogasawara Y; Park SY; Tanaka Y; Kusuhara H; Mizokami M; Sureau C; Wakita T
    J Hepatol; 2017 Apr; 66(4):685-692. PubMed ID: 27890789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
    Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
    J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
    Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
    Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
    Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
    Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of the bile acid transporter and hepatitis B virus receptor Na+/taurocholate cotransporting polypeptide (NTCP) in hepatocytes.
    König A; Döring B; Mohr C; Geipel A; Geyer J; Glebe D
    J Hepatol; 2014 Oct; 61(4):867-75. PubMed ID: 24845614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
    Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
    J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP).
    Watashi K; Sluder A; Daito T; Matsunaga S; Ryo A; Nagamori S; Iwamoto M; Nakajima S; Tsukuda S; Borroto-Esoda K; Sugiyama M; Tanaka Y; Kanai Y; Kusuhara H; Mizokami M; Wakita T
    Hepatology; 2014 May; 59(5):1726-37. PubMed ID: 24375637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide.
    Okuyama-Dobashi K; Kasai H; Tanaka T; Yamashita A; Yasumoto J; Chen W; Okamoto T; Maekawa S; Watashi K; Wakita T; Ryo A; Suzuki T; Matsuura Y; Enomoto N; Moriishi K
    Sci Rep; 2015 Nov; 5():17047. PubMed ID: 26592202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective hepatitis B and D virus entry inhibitors from the group of pentacyclic lupane-type betulin-derived triterpenoids.
    Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Alakurtti S; Yli-Kauhaluoma J; Glebe D; Geyer J
    Sci Rep; 2020 Dec; 10(1):21772. PubMed ID: 33303817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to inhibit entry of HBV and HDV into hepatocytes.
    Urban S; Bartenschlager R; Kubitz R; Zoulim F
    Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.
    Yan H; Zhong G; Xu G; He W; Jing Z; Gao Z; Huang Y; Qi Y; Peng B; Wang H; Fu L; Song M; Chen P; Gao W; Ren B; Sun Y; Cai T; Feng X; Sui J; Li W
    Elife; 2012 Nov; 3():. PubMed ID: 25409679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From DCPD to NTCP: the long journey towards identifying a functional hepatitis B virus receptor.
    Li J; Tong S
    Clin Mol Hepatol; 2015 Sep; 21(3):193-9. PubMed ID: 26523264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTCP opens the door for hepatitis B virus infection.
    Yan H; Liu Y; Sui J; Li W
    Antiviral Res; 2015 Sep; 121():24-30. PubMed ID: 26071008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
    Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
    PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 6 inhibits HBV entry through NTCP down regulation.
    Bouezzedine F; Fardel O; Gripon P
    Virology; 2015 Jul; 481():34-42. PubMed ID: 25765005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new hepatoma cell line exhibiting high susceptibility to hepatitis B virus infection.
    Ueda Y; Gu W; Dansako H; Nishitsuji H; Satoh S; Shimotohno K; Kato N
    Biochem Biophys Res Commun; 2019 Jul; 515(1):156-162. PubMed ID: 31133379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Woodchuck sodium taurocholate cotransporting polypeptide supports low-level hepatitis B and D virus entry.
    Fu L; Hu H; Liu Y; Jing Z; Li W
    Virology; 2017 May; 505():1-11. PubMed ID: 28213271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.